Uncategorized
Santen seeks European marketing authorization for intravitreal sirolimus
The European Medicines Agency has accepted a marketing authorization application from Santen Pharmaceutical for the use of intravitreal sirolimus 440 μg for the treatment of noninfectious uveitis of the posterior segment, the company announced in a press release.